Taxifolin attenuates liver fibrosis by regulating the phosphorylation of NDRG1 at Thr328 via hepatocyte-stellate cell cross talk.
- Author:
Chuan DING
1
;
Zeping WANG
2
;
Kao SHI
2
;
Sunan LI
2
;
Xinyue DOU
2
;
Yan NING
2
;
Gang CHENG
2
;
Qiao YANG
2
;
Xianan SANG
2
;
Mengyun PENG
2
;
Qiang LYU
2
;
Lu WANG
2
;
Xin HAN
1
;
Gang CAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Cross-talk; HSCs; Hepatocyte; Liver fibrosis; Liver injury; Proteomics; Taxifolin; pNDRG1T328
- From: Acta Pharmaceutica Sinica B 2025;15(4):2059-2076
- CountryChina
- Language:English
- Abstract: Taxifolin (TAX) is a natural compound known for its liver protection effect, but the mechanism remains unknown. Phosphorylated proteomics analyses discovered that the phosphorylation level of NDRG1 at T328 was a key event of TAX-improved liver fibrosis. We established models with NDRG1 knockout (KO) in vivo and in vitro, demonstrating that NDRG1 KO attenuated the development of hepatocyte injury, and combining NDRG1 KO and TAX administration did not result in a reduction in protection against liver injury. Cellular thermal shift assay and surface plasma resonance analysis showed that TAX directly binds to NDRG1 rather than its upstream kinase, subsequently demonstrating that TAX regulated phosphorylation of NDRG1 at T328 through binding to its C289 site. NDRG1 T328A (phosphorylated mutation) and T328E (mimic phosphorylation) in vivo and in vitro confirmed that pNDRG1T328 exacerbates hepatocyte injury along with DNA damage, inflammatory response, and apoptosis, thereby contributing to hepatic stellate cells (HSCs) activation. In contrast, TAX can inhibit the above pathological abnormalities and block hepatocyte injury-triggered HSCs activation and fibrosis. Overall, TAX is a potent liver protection drug primarily targeting NDRG1 and inhibiting pNDRG1T328 in hepatocytes.
